The net asset value per HBM share (NAV) increased by 30.5 percent to CHF 263.98 in the first six months of the financial year 2020/2021 ending on 31 March. The share price rose by 46.2 percent to CHF 270.00. The four IPO’s of Cathay Biotech, Harmony Biosciences, ALX Oncology and iTeos Therapeutics as well as the five trade sales of Immunomedics, Corvidia Therapeutics, Forbius, Shriji Polymers and Vitaeris contributed significantly to this result.

Based on the above key figures, HBM Healthcare Investments expects a significantly higher net profit of around CHF 441 million for the first half year. In the same period last year, net profit was CHF 102.5 million.

These figures are a preliminary result based on the current status of the closing process. The final result will be published with the Half-Year Report September 2020
on 23 October 2020.

Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com.